A citation-based method for searching scientific literature

Chiun Hsu, Se-Hoon Lee, Samuel Ejadi, Caroline Even, Roger B Cohen, Christophe Le Tourneau, Janice M Mehnert, Alain Algazi, Emilie M J van Brummelen, Sanatan Saraf, Pradeep Thanigaimani, Jonathan D Cheng, Aaron R Hansen. J Clin Oncol 2017
Times Cited: 230







List of co-cited articles
835 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742).
Brigette B Y Ma, Wan-Teck Lim, Boon-Cher Goh, Edwin P Hui, Kwok-Wai Lo, Adam Pettinger, Nathan R Foster, Jonathan W Riess, Mark Agulnik, Alex Y C Chang,[...]. J Clin Oncol 2018
207
74

Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials.
Wenfeng Fang, Yunpeng Yang, Yuxiang Ma, Shaodong Hong, Lizhu Lin, Xiaohui He, Jianping Xiong, Ping Li, Hongyun Zhao, Yan Huang,[...]. Lancet Oncol 2018
217
53

Nasopharyngeal carcinoma.
Yu-Pei Chen, Anthony T C Chan, Quynh-Thu Le, Pierre Blanchard, Ying Sun, Jun Ma. Lancet 2019
935
39

Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial.
Li Zhang, Yan Huang, Shaodong Hong, Yunpeng Yang, Gengsheng Yu, Jun Jia, Peijian Peng, Xuan Wu, Qing Lin, Xuping Xi,[...]. Lancet 2016
279
36

Efficacy, Safety, and Correlative Biomarkers of Toripalimab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial (POLARIS-02).
Feng-Hua Wang, Xiao-Li Wei, Jifeng Feng, Qi Li, Nong Xu, Xi-Chun Hu, Wangjun Liao, Yi Jiang, Xiao-Yan Lin, Qing-Yuan Zhang,[...]. J Clin Oncol 2021
59
38

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
Freddie Bray, Jacques Ferlay, Isabelle Soerjomataram, Rebecca L Siegel, Lindsey A Torre, Ahmedin Jemal. CA Cancer J Clin 2018
19

Exome and genome sequencing of nasopharynx cancer identifies NF-κB pathway activating mutations.
Yvonne Y Li, Grace T Y Chung, Vivian W Y Lui, Ka-Fai To, Brigette B Y Ma, Chit Chow, John K S Woo, Kevin Y Yip, Jeongsun Seo, Edwin P Hui,[...]. Nat Commun 2017
173
18

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck.
Robert L Ferris, George Blumenschein, Jerome Fayette, Joel Guigay, A Dimitrios Colevas, Lisa Licitra, Kevin Harrington, Stefan Kasper, Everett E Vokes, Caroline Even,[...]. N Engl J Med 2016
18

Nasopharyngeal carcinoma.
Melvin L K Chua, Joseph T S Wee, Edwin P Hui, Anthony T C Chan. Lancet 2016
812
16


Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma.
Yuan Zhang, Lei Chen, Guo-Qing Hu, Ning Zhang, Xiao-Dong Zhu, Kun-Yu Yang, Feng Jin, Mei Shi, Yu-Pei Chen, Wei-Han Hu,[...]. N Engl J Med 2019
366
14

Management of Nasopharyngeal Carcinoma: Current Practice and Future Perspective.
Anne W M Lee, Brigette B Y Ma, Wai Tong Ng, Anthony T C Chan. J Clin Oncol 2015
437
13

EBV-driven LMP1 and IFN-γ up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy.
Wenfeng Fang, Jianwei Zhang, Shaodong Hong, Jianhua Zhan, Nan Chen, Tao Qin, Yanna Tang, Yaxiong Zhang, Shiyang Kang, Ting Zhou,[...]. Oncotarget 2014
249
13

Single-cell transcriptomics reveals regulators underlying immune cell diversity and immune subtypes associated with prognosis in nasopharyngeal carcinoma.
Yu-Pei Chen, Jian-Hua Yin, Wen-Fei Li, Han-Jie Li, Dong-Ping Chen, Cui-Juan Zhang, Jia-Wei Lv, Ya-Qin Wang, Xiao-Min Li, Jun-Yan Li,[...]. Cell Res 2020
91
14

Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial.
Hai-Qiang Mai, Qiu-Yan Chen, Dongping Chen, Chaosu Hu, Kunyu Yang, Jiyu Wen, Jingao Li, Ying-Rui Shi, Feng Jin, Ruilian Xu,[...]. Nat Med 2021
59
22

Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysis.
Pierre Blanchard, Anne Lee, Sophie Marguet, Julie Leclercq, Wai Tong Ng, Jun Ma, Anthony T C Chan, Pei-Yu Huang, Ellen Benhamou, Guopei Zhu,[...]. Lancet Oncol 2015
468
11

The genomic landscape of nasopharyngeal carcinoma.
De-Chen Lin, Xuan Meng, Masaharu Hazawa, Yasunobu Nagata, Ana Maria Varela, Liang Xu, Yusuke Sato, Li-Zhen Liu, Ling-Wen Ding, Arjun Sharma,[...]. Nat Genet 2014
226
11

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Barbara Burtness, Kevin J Harrington, Richard Greil, Denis Soulières, Makoto Tahara, Gilberto de Castro, Amanda Psyrri, Neus Basté, Prakash Neupane, Åse Bratland,[...]. Lancet 2019
996
11

Immune checkpoint inhibitors in advanced nasopharyngeal carcinoma: Beyond an era of chemoradiation?
Liam Masterson, James Howard, Jazmina Gonzalez-Cruz, Christopher Jackson, Catherine Barnett, Lewis Overton, Howard Liu, Rahul Ladwa, Fiona Simpson, Margie McGrath,[...]. Int J Cancer 2020
31
35

Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial.
Tanguy Y Seiwert, Barbara Burtness, Ranee Mehra, Jared Weiss, Raanan Berger, Joseph Paul Eder, Karl Heath, Terrill McClanahan, Jared Lunceford, Christine Gause,[...]. Lancet Oncol 2016
11

Whole-exome sequencing identifies multiple loss-of-function mutations of NF-κB pathway regulators in nasopharyngeal carcinoma.
Hong Zheng, Wei Dai, Arthur Kwok Leung Cheung, Josephine Mun Yee Ko, Rebecca Kan, Bonnie Wing Yan Wong, Merrin Man Long Leong, Mingdan Deng, Tommy Chin Tung Kwok, Jimmy Yu-Wai Chan,[...]. Proc Natl Acad Sci U S A 2016
108
10

Comparison of five cisplatin-based regimens frequently used as the first-line protocols in metastatic nasopharyngeal carcinoma.
Ying Jin, Yan-Xia Shi, Xiu-Yu Cai, Xi-Ya Xia, Yu-Chen Cai, Ye Cao, Wei-Dong Zhang, Wei-Han Hu, Wen-Qi Jiang. J Cancer Res Clin Oncol 2012
80
12

Adoptive T-cell transfer and chemotherapy in the first-line treatment of metastatic and/or locally recurrent nasopharyngeal carcinoma.
Whay-Kuang Chia, Marissa Teo, Who-Whong Wang, Bernett Lee, Soo-Fan Ang, Wai-Meng Tai, Chit-Lai Chee, Joanna Ng, Rebecca Kan, Wan-Teck Lim,[...]. Mol Ther 2014
153
10

The prognostic significance of PD-L1 and PD-1 expression in patients with nasopharyngeal carcinoma: a systematic review and meta-analysis.
Zi-Lu Huang, Shan Liu, Guan-Nan Wang, Shuo-Han Zheng, Shi-Rong Ding, Ya-Lan Tao, Chen Chen, Song-Ran Liu, Xin Yang, Hui Chang,[...]. Cancer Cell Int 2019
29
34

Efficacy and Safety of Locoregional Radiotherapy With Chemotherapy vs Chemotherapy Alone in De Novo Metastatic Nasopharyngeal Carcinoma: A Multicenter Phase 3 Randomized Clinical Trial.
Rui You, You-Ping Liu, Pei-Yu Huang, Xiong Zou, Rui Sun, Yu-Xiang He, Yi-Shan Wu, Guo-Ping Shen, Hong-Dan Zhang, Chong-Yang Duan,[...]. JAMA Oncol 2020
79
12

Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.
Hyuna Sung, Jacques Ferlay, Rebecca L Siegel, Mathieu Laversanne, Isabelle Soerjomataram, Ahmedin Jemal, Freddie Bray. CA Cancer J Clin 2021
10

Tumor cells PD-L1 expression as a favorable prognosis factor in nasopharyngeal carcinoma patients with pre-existing intratumor-infiltrating lymphocytes.
Qian Zhu, Mu-Yan Cai, Chang-Long Chen, Hao Hu, Huan-Xin Lin, Min Li, De-Sheng Weng, Jing-Jing Zhao, Ling Guo, Jian-Chuan Xia. Oncoimmunology 2017
51
17

Analysis of Plasma Epstein-Barr Virus DNA in Nasopharyngeal Cancer After Chemoradiation to Identify High-Risk Patients for Adjuvant Chemotherapy: A Randomized Controlled Trial.
Anthony T C Chan, Edwin P Hui, Roger K C Ngan, Stewart Y Tung, Ashley C K Cheng, Wai T Ng, Victor H F Lee, Brigette B Y Ma, Hoi C Cheng, Frank C S Wong,[...]. J Clin Oncol 2018
100
9

Systemic therapies for recurrent or metastatic nasopharyngeal carcinoma: a systematic review.
A Prawira, S F Oosting, T W Chen, K A Delos Santos, R Saluja, L Wang, L L Siu, K K W Chan, A R Hansen. Br J Cancer 2017
43
20

Management of locally recurrent nasopharyngeal carcinoma.
Anne W M Lee, Wai Tong Ng, Jimmy Y W Chan, June Corry, Antti Mäkitie, William M Mendenhall, Alessandra Rinaldo, Juan P Rodrigo, Nabil F Saba, Primož Strojan,[...]. Cancer Treat Rev 2019
98
9

Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial.
Ying Sun, Wen-Fei Li, Nian-Yong Chen, Ning Zhang, Guo-Qing Hu, Fang-Yun Xie, Yan Sun, Xiao-Zhong Chen, Jin-Gao Li, Xiao-Dong Zhu,[...]. Lancet Oncol 2016
515
9

Single-cell transcriptomic analysis defines the interplay between tumor cells, viral infection, and the microenvironment in nasopharyngeal carcinoma.
Shanzhao Jin, Ruoyan Li, Ming-Yuan Chen, Chao Yu, Lin-Quan Tang, Yan-Min Liu, Jiang-Ping Li, Yi-Na Liu, Yi-Ling Luo, Yifan Zhao,[...]. Cell Res 2020
44
20

Genomic Analysis of Nasopharyngeal Carcinoma Reveals TME-Based Subtypes.
Li Zhang, Kenzie D MacIsaac, Ting Zhou, Pei-Yu Huang, Chunlin Xin, Jason R Dobson, Kun Yu, Derek Y Chiang, Yue Fan, Marc Pelletier,[...]. Mol Cancer Res 2017
71
12

Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study.
Ezra E W Cohen, Denis Soulières, Christophe Le Tourneau, José Dinis, Lisa Licitra, Myung-Ju Ahn, Ainara Soria, Jean-Pascal Machiels, Nicolas Mach, Ranee Mehra,[...]. Lancet 2019
740
9

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
E A Eisenhauer, P Therasse, J Bogaerts, L H Schwartz, D Sargent, R Ford, J Dancey, S Arbuck, S Gwyther, M Mooney,[...]. Eur J Cancer 2009
9

Prognostic Model for Stratification of Radioresistant Nasopharynx Carcinoma to Curative Salvage Radiotherapy.
You Quan Li, Yun Ming Tian, Sze Huey Tan, Ming Zhu Liu, Grace Kusumawidjaja, Enya H W Ong, Chong Zhao, Terence W K Tan, Kam Weng Fong, Kiattisa Sommat,[...]. J Clin Oncol 2018
50
16

What Is the Best Treatment of Locally Advanced Nasopharyngeal Carcinoma? An Individual Patient Data Network Meta-Analysis.
Laureen Ribassin-Majed, Sophie Marguet, Anne W M Lee, Wai Tong Ng, Jun Ma, Anthony T C Chan, Pei-Yu Huang, Guopei Zhu, Daniel T T Chua, Yong Chen,[...]. J Clin Oncol 2017
185
8

PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies.
Benjamin J Chen, Bjoern Chapuy, Jing Ouyang, Heather H Sun, Margaretha G M Roemer, Mina L Xu, Hongbo Yu, Christopher D M Fletcher, Gordon J Freeman, Margaret A Shipp,[...]. Clin Cancer Res 2013
582
8

Translational genomics of nasopharyngeal cancer.
Chi Man Tsang, Vivian Wai Yan Lui, Jeffrey P Bruce, Trevor J Pugh, Kwok Wai Lo. Semin Cancer Biol 2020
46
17

Single cell RNA-seq reveals the landscape of tumor and infiltrating immune cells in nasopharyngeal carcinoma.
Jin Zhao, Can Guo, Fang Xiong, Jianjun Yu, Junshang Ge, Hui Wang, Qianjin Liao, Yujuan Zhou, Qian Gong, Bo Xiang,[...]. Cancer Lett 2020
56
14

Co-expression of PD-1 and PD-L1 predicts poor outcome in nasopharyngeal carcinoma.
Jianwei Zhang, Wenfeng Fang, Tao Qin, Yunpeng Yang, Shaodong Hong, Wenhua Liang, Yuxiang Ma, Hongyun Zhao, Yan Huang, Cong Xue,[...]. Med Oncol 2015
78
10

Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099.
M Al-Sarraf, M LeBlanc, P G Giri, K K Fu, J Cooper, T Vuong, A A Forastiere, G Adams, W A Sakr, D E Schuller,[...]. J Clin Oncol 1998
8


Gemcitabine in metastatic nasopharyngeal carcinoma of the undifferentiated type.
K F Foo, E H Tan, S S Leong, J T S Wee, T Tan, K W Fong, L Koh, B C Tai, L G Lian, D Machin. Ann Oncol 2002
98
7

Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: A phase III multicentre randomised controlled trial.
Su-Mei Cao, Qi Yang, Ling Guo, Hai-Qiang Mai, Hao-Yuan Mo, Ka-Jia Cao, Chao-Nan Qian, Chong Zhao, Yan-Qun Xiang, Xiu-Ping Zhang,[...]. Eur J Cancer 2017
170
7

Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes.
Patrizia Comoli, Paolo Pedrazzoli, Rita Maccario, Sabrina Basso, Ornella Carminati, Massimo Labirio, Roberta Schiavo, Simona Secondino, Chiara Frasson, Cesare Perotti,[...]. J Clin Oncol 2005
185
7

The efficacy and safety of PD-1/PD-L1 inhibitors in patients with recurrent or metastatic nasopharyngeal carcinoma: A systematic review and meta-analysis.
Bi-Cheng Wang, Ru-Bo Cao, Chen Fu, Wang-Bing Chen, Pin-Dong Li, Guo-He Lin, Xiao-Jun Qian, Yun-Tian Li, Quentin Liu. Oral Oncol 2020
11
63

The immunologic advantage of recurrent nasopharyngeal carcinoma from the viewpoint of Galectin-9/Tim-3-related changes in the tumour microenvironment.
Tseng-Cheng Chen, Chao-Hsien Chen, Cheng-Ping Wang, Pei-Hsuan Lin, Tsung-Lin Yang, Pei-Jen Lou, Jenq-Yuh Ko, Chen-Tu Wu, Yih-Leong Chang. Sci Rep 2017
19
36

Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort.
Laura Q M Chow, Robert Haddad, Shilpa Gupta, Amit Mahipal, Ranee Mehra, Makoto Tahara, Raanan Berger, Joseph Paul Eder, Barbara Burtness, Se-Hoon Lee,[...]. J Clin Oncol 2016
530
7

LMP1-mediated glycolysis induces myeloid-derived suppressor cell expansion in nasopharyngeal carcinoma.
Ting-Ting Cai, Shu-Biao Ye, Yi-Na Liu, Jia He, Qiu-Yan Chen, Hai-Qiang Mai, Chuan-Xia Zhang, Jun Cui, Xiao-Shi Zhang, Pierre Busson,[...]. PLoS Pathog 2017
73
9


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.